Neurotrophic keratitis is a relatively rare disease that can be difficult to manage, and treatment varies depending on disease stage.
In recent years, the development of Oxervate (cenegermin-bkbj ophthalmic solution 0.002%, Dompé U.S.) has transformed the treatment landscape, becoming one of the greatest advancements for patients with neurotrophic keratitis, according to Cory J. Lappin, OD, MS, FAAO, an optometrist at Phoenix Eye Care and the Dry Eye Center of Arizona.